CCA
ABBV icon

Cravens & Co Advisors’s AbbVie ABBV Stock Holding History

Cravens & Co Advisors’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-4,866
Closed -$1.02M – 56
2025
Q1 		$1.02M Sell
4,866
-103
-2% -$20K 0.79% 29
2024
Q4 		$883K Buy
4,969
+107
+2% +$19.7K 0.67% 30
2024
Q3 		$960K Sell
4,862
-2,041
-30% -$381K 0.74% 32
2024
Q2 		$1.18M Buy
6,903
+515
+8% +$85.3K 0.88% 20
2024
Q1 		$1.16M Sell
6,388
-68
-1% -$11.7K 0.97% 24
2023
Q4 		$1M Sell
6,456
-100
-2% -$14.6K 0.86% 25
2023
Q3 		$977K Buy
6,556
+89
+1% +$13.1K 0.92% 23
2023
Q2 		$871K Sell
6,467
-9
-0.1% -$1.32K 0.8% 27
2023
Q1 		$1.03M Buy
6,476
+26
+0.4% +$3.98K 0.96% 15
2022
Q4 		$1.04M Buy
+6,450
New +$989K 0.96% 16

Other funds holding ABBV

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM

Cravens & Co Advisors's ABBV Position: Q2 2025 in Review

Cravens & Co Advisors sold out of AbbVie (ABBV) in Q2 2025, closing a stake of 4,866 shares — an estimated $1.02M sold.

Cravens & Co Advisors first reported a position in ABBV in Q4 2022 and held it in 10 quarters. The position peaked at $1.18M in Q2 2024. 3,780 funds tracked by Wall St. Rank hold ABBV as of Q2 2025.

  • Cravens & Co Advisors reported no remaining AbbVie position as of Q2 2025 after selling out during the quarter.
  • Cravens & Co Advisors sold 4,866 AbbVie shares in Q2 2025, an estimated $1.02M.
  • Cravens & Co Advisors first reported a position in AbbVie in Q4 2022 and held it in 10 quarters.
  • Cravens & Co Advisors's AbbVie position peaked at $1.18M in Q2 2024.
  • 3,780 funds tracked by Wall St. Rank held AbbVie as of Q2 2025.

Based on Cravens & Co Advisors's 13F filing for Q2 2025, filed 12 Aug 2025.